Vonex begins Oper8tor beta development

|

Published 25-JUN-2018 14:05 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Emerging telco play Vonex Limited (ASX:VN8) today informed the market that is has begun development of its Oper8tor application.

The announcement comes off the back of VN8’s successful listing on the ASX earlier this month.

It should be noted that Vonex remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.

The move will directly impact VN8’s current development baseline, providing a boost to its software architecture, data, functional programming machine learning and mobile development capability.

Beta testing will kick off from October 2018 and will involve up to 5,000 controlled users targeting data collection, bug reporting, online marketing and stress testing on elastic servers. The company has also indicated that beta testing will include tweaking to work-in-progress user interface functionality.

In-house engineers and developers will be employed by VN8 during the development process, until a minimum viable product is ready for soft-launch in Western Europe in early 2019.

This region was selected due to its concentrated population and advanced economies which feature high mobile phone adoption.

VN8 Managing Director Matthew Fahey commented on the announcement, “Having successfully raised $6 million in our recent IPO, we are now well funded to progress with the development of this cutting-edge application, the only mobile app in the world that Vonex is aware of allowing multiple voice apps to operate seamlessly together.

“I look forward to updating investors as Vonex progresses through the beta development process towards the controlled testing stage.”

The company believes that the bulk of development costs for the Oper8tor app will be deemed eligible expenditure for R&D tax incentive purposes.

About Oper8tor

Oper8tor is a one stop communication aggregator app, which allows conversations to transpire across multiple platforms at once.

VN8 has identified a clear issue when it comes to multiple parties participating in a conference call using differing technologies, and the time delays caused by technical troubleshooting.

The Oper8tor app targets both consumer and communication technology providers, and can be deployed worldwide. VN8 owns the IP behind the app, holding global patents pending in relation to the technology.

As more competitors and alternatives enter the market, the greater the need for a communication aggregator app becomes.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X